Looking aheadAs mentioned by Nick, his focus is places outside the US, so Pharmala will continue to truck ahead. Nothing has really changed for them. There are many drugs that are approved In Europe and Canada that are not approved in the US. As Nick pointed out in his last interview the cost to do business in the US is about $100 million or more for clinical trials. So his focus has always been other countries. And other countries will moving to do their own clinical studies which is where Pharmala comes in as a possible supplier or partner.